In the current month, BIAF has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BIAF average Analyst price target in the last month is 6.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
Strong Buy
0
0
0
0
0
0
0
0
Buy
0
0
0
0
0
0
0
0
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
0
0
0
BIAF Analyst Rating for Peer Comparison
Updated: Nov 5, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
Stryker Corp
SYK
10
14
6
0
0
30
Dexcom Inc
DXCM
13
12
4
0
0
29
Medtronic PLC
MDT
8
11
10
0
0
29
Abbott Laboratories
ABT
11
13
4
0
0
28
Guardant Health Inc
GH
12
14
2
0
0
28
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Zimmer Biomet Holdings Inc
ZBH
2
5
20
0
0
27
Insulet Corp
PODD
7
7
12
0
0
26
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
12
4
0
0
21
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
Forecast
-2.40
-2.10
-2.10
Actual
-0.81
-9.66
-5.89
Surprise
+66.34%
-360.01%
-180.37%
FAQs
What is the analyst rating for bioAffinity Technologies Inc?
Based on the ratings of bioAffinity Technologies Inc's stock from 0 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.